Table 1.
Effect of socio-demographic, women reproductive and tumour characteristics on breast cancer patient appropriate treatment
| Patients | Patients appropriately | Crude analysis | Adjusted analysis* | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| assessed | treated | Odds ratio (95% CI) | Odds ratio (95% CI) | ||||||||
| n | n | Proportion (95% CI) | |||||||||
| Overall | 1719 | 919 | 0.5 | (0.5 - | 0.6) | ||||||
| 1. Socio-demographic and women reproductive characteristics | |||||||||||
| Centre | |||||||||||
| Casablanca | 696 | 218 | 0.3 | (0.3 - | 0.3) | 1.00 | 1.00 | ||||
| Rabat | 1023 | 701 | 0.7 | (0.7 - | 0.7) | 4.84 | (3.88 - | 5.92) | 6.07 | (4.72 - | 7.73) |
| Period | |||||||||||
| 2008–2012 | 725 | 471 | 0.6 | (0.6 - | 0.7) | 1.00 | 1.00 | ||||
| 2013–2017 | 994 | 448 | 0.5 | (0.4 - | 0.5) | 0.45 | (0.36 - | 0.54) | 0.37 | (0.27 - | 0.49) |
| Age at diagnosis (years) | |||||||||||
| < 40 | 304 | 170 | 0.6 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| 40–49 | 605 | 346 | 0.6 | (0.5 - | 0.6) | 1.01 | (0.75 - | 1.33) | 1.07 | (0.73 - | 1.46) |
| 50–59 | 487 | 258 | 0.5 | (0.5 - | 0.6) | 0.83 | (0.60 - | 1.11) | 0.72 | (0.45 - | 1.07) |
| 60–69 | 229 | 104 | 0.5 | (0.4 - | 0.5) | 0.60 | (0.39 - | 0.83) | 0.51 | (0.29 - | 0.81) |
| 70+ | 94 | 41 | 0.4 | (0.3 - | 0.5) | 0.62 | (0.36 - | 0.97) | 0.44 | (0.20 - | 0.77) |
| Place of residence | |||||||||||
| Urban | 1379 | 737 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| Semi-urban | 146 | 76 | 0.5 | (0.4 - | 0.6) | 0.95 | (0.65 - | 1.33) | 1.21 | (0.77 - | 1.76) |
| Rural | 194 | 106 | 0.5 | (0.5 - | 0.6) | 1.07 | (0.77 - | 1.44) | 1.24 | (0.81 - | 1.74) |
| Social security coverage | |||||||||||
| None | 573 | 330 | 0.6 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| RAMED | 862 | 431 | 0.5 | (0.5 - | 0.5) | 0.74 | (0.58 - | 0.92) | 1.14 | (0.80 - | 1.57) |
| CNOPS or CNSS | 272 | 151 | 0.6 | (0.5 - | 0.6) | 0.97 | (0.69 - | 1.31) | 0.96 | (0.59 - | 1.38) |
| Marital status | |||||||||||
| Never | 271 | 140 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| Ever | 1442 | 777 | 0.5 | (0.5 - | 0.6) | 1.04 | (0.76 - | 1.34) | 1.24 | (0.77 - | 1.82) |
| Parity | |||||||||||
| None | 432 | 230 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| 1–2 | 433 | 230 | 0.5 | (0.5 - | 0.6) | 0.89 | (0.66 - | 1.19) | 0.75 | (0.46 - | 1.08) |
| 3–4 | 455 | 240 | 0.5 | (0.5 - | 0.6) | 0.84 | (0.60 - | 1.09) | 0.75 | (0.47 - | 1.09) |
| 5+ | 392 | 218 | 0.6 | (0.5 - | 0.6) | 1.00 | (0.72 - | 1.32) | 0.91 | (0.57 - | 1.36) |
| Menopausal status | |||||||||||
| Pre | 928 | 494 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| Post | 785 | 424 | 0.5 | (0.5 - | 0.6) | 0.95 | (0.76 - | 1.14) | 1.18 | (0.84 - | 1.62) |
| Family history of breast cancer | |||||||||||
| No | 1490 | 785 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| Yes | 222 | 133 | 0.6 | (0.5 - | 0.7) | 1.40 | (0.99 - | 1.89) | 1.42 | (0.96 - | 2.01) |
| 2. Tumour characteristics | |||||||||||
| Pathological T stage | |||||||||||
| T1 | 378 | 207 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| T2 | 987 | 565 | 0.6 | (0.5 - | 0.6) | 1.14 | (0.87 - | 1.45) | 1.04 | (0.76 - | 1.37) |
| T3 | 230 | 109 | 0.5 | (0.4 - | 0.5) | 0.74 | (0.51 - | 1.01) | 0.67 | (0.41 - | 0.96) |
| T4 | 116 | 38 | 0.3 | (0.2 - | 0.4) | 0.40 | (0.23 - | 0.60) | 0.35 | (0.19 - | 0.56) |
| Pathological N stage | |||||||||||
| N0 | 763 | 424 | 0.6 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| N1 | 487 | 257 | 0.5 | (0.5 - | 0.6) | 0.89 | (0.68 - | 1.11) | 0.83 | (0.61 - | 1.08) |
| N2 | 314 | 168 | 0.5 | (0.5 - | 0.6) | 0.95 | (0.71 - | 1.24) | 0.75 | (0.52 - | 1.02) |
| N3 | 148 | 70 | 0.5 | (0.4 - | 0.6) | 0.72 | (0.48 - | 1.02) | 0.60 | (0.35 - | 0.88) |
| Stage at diagnosis | |||||||||||
| I | 201 | 105 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| II | 855 | 503 | 0.6 | (0.6 - | 0.6) | 1.30 | (0.92 - | 1.76) | 1.22 | (0.81 - | 1.70) |
| III | 657 | 311 | 0.5 | (0.4 - | 0.5) | 0.82 | (0.58 - | 1.13) | 0.62 | (0.40 - | 0.87) |
| Tumour type | |||||||||||
| Ductal carcinoma | 1475 | 830 | 0.6 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| Lobular carcinoma | 78 | 34 | 0.4 | (0.3 - | 0.6) | 0.58 | (0.33 - | 0.88) | 0.77 | (0.40 - | 1.28) |
| Others | 162 | 52 | 0.3 | (0.2 - | 0.4) | 0.40 | (0.27 - | 0.55) | 0.41 | (0.26 - | 0.61) |
| Tumour differentiation | |||||||||||
| Well | 140 | 83 | 0.6 | (0.5 - | 0.7) | 1.00 | 1.00 | ||||
| Moderately | 1001 | 505 | 0.5 | (0.5 - | 0.5) | 0.76 | (0.48 - | 1.08) | 1.02 | (0.61 - | 1.50) |
| Poorly | 570 | 328 | 0.6 | (0.5 - | 0.6) | 0.96 | (0.60 - | 1.39) | 1.19 | (0.68 - | 1.79) |
| Molecular subtype | |||||||||||
| ER and/or PR positive, and HER2 negative | 932 | 508 | 0.5 | (0.5 - | 0.6) | 1.00 | 1.00 | ||||
| ER and/or PR positive, and HER2 positive | 369 | 168 | 0.5 | (0.4 - | 0.5) | 0.67 | (0.51 - | 0.87) | 0.69 | (0.48 - | 0.92) |
| ER and PR negative, and HER2 positive | 143 | 79 | 0.6 | (0.5 - | 0.6) | 0.98 | (0.64 - | 1.40) | 1.05 | (0.62 - | 1.58) |
| Triple negative | 258 | 156 | 0.6 | (0.5 - | 0.7) | 1.24 | (0.89 - | 1.69) | 1.48 | (0.99 - | 2.13) |
ER: Estrogen receptors; PR: Progesterone receptors; HER2: human epidermal growth factor receptor 2; * All appropriate patients characteristics included in the multivariate regression model